Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
AI Guidelines for Physicians
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Breast Cancer
•
Radiation Oncology
Is xeroderma pigmentosum a contraindication for adjuvant radiation therapy to the breast in the breast conservation setting?
Answer from: Radiation Oncologist at Community Practice
It’s not a contraindication to RT as DSB caused by ionizing RT is not the same as damage caused by exposure to UV rays.
Sign In
or
Register
to read more
8736
Related Questions
Would you recommend PMRT to a clinically node positive (biopsy proven axillary node and indeterminate single IMN node) BRCA positive patient with multiple medical co-morbidities including scleroderma and ILD who is treated with neoadjuvant chemotherapy (NAC) and mastectomy who converts to ypT0/ypN0?
How do you approach the discussion about the potential risks of radiation therapy exposure and the development of secondary malignancies for patients with germline BRCA1/2 mutations?
Is stage I B/L breast, ER+ cancer a contraindication to breast radiation omission after breast conservation surgery?
For patients between 40-49 years old who undergo lumpectomy, how do you choose between offering PBI per the updated PBI guidelines or boosting based on boost guidelines?
What are your top takeaways in Radiation Oncology from SABCS 2024?
Have the 10-year results from UK FAST-Forward presented at ESTRO 2025 impacted your practice with regard to patient selection?
Is re-excision of residual disease ever itself an indication for PMRT?
What is your approach to women with breast cancer who opts for a staged approach with up-front lumpectomy and SLN biopsy (pN-) when there are indications for adjuvant radiation therapy but she plans for a later mastectomy (=>6 months)?
Does pre-chemotherapy extent of nodal involvement impact your decision to offer adjuvant radiation in cN1, ypN0 triple-negative breast cancer?
Is FAST-Forward/ultra-hypofractionation suitable for an early-stage breast patient after a lumpectomy with oncoplastic reduction?